前列腺特异性膜抗原PSMA - 知乎 - 知乎专栏
前列腺特异性膜抗原（PMSA），又称为 谷氨酸羧肽酶II （GCPII），也被称为 叶酸水解酶 （FolH1），是一种锌依赖性金属蛋白酶，PSMA主要在前列腺癌细胞中表达，前列腺腺癌中 …
2020年10月1日 · • Provides updated guidance regarding the level of detail expected in PMSA reports to the ACO. These changes have eliminated the need for the Government Contract …
物業管理業監管局 | 主頁 - PMSA
如對「服務」提供的答案有任何疑問，請於辦公時間內致電「監管局」熱綫3696 1111 或電郵至[email protected]查詢。 如你明白及同意本免責聲明，請按「確認」開始對話。
Proviso Mathematics & Science Academy / Homepage
PMSA Students Honored at Inaugural Illinois AP Day at the Capitol. Comments (-1) more . Upcoming Events. Tomorrow. Spring Break - No School. Tuesday. Spring Break - No School. …
First in human evaluation of PSMA-62: Intraindividual comparison …
2024年6月1日 · [Ga-68]-PSMA-62 is a novel PSMA targeting radioligand with presumed favourable pharmacokinetics based on preclinical data. This clinical study presents an …
Preclinical efficacy studies of DS-1062a, a novel TROP2-targeting ...
Results: DS-1062a showed in vitro cell growth inhibitory activity to TROP2-positive tumor cells (CFPAC-1, BxPC-3 (pancreas adenocarcinoma)) with IC50 values of 706 ng/mL and 74.6 …
Meeting Abstract: 2019 ASCO Annual Meeting I - ASCO Publications
2019年5月26日 · Background: DS-1062a is a trophoblast cell-surface antigen 2 (TROP2)-targeting antibody drug conjugate. TROP2 is highly expressed in epithelial cancers, including …
68Ga 标记的聚乙二醇化 PSMA 多聚体改善前列腺癌药代动力学的 …
结果表明，PEG4 和 PSMA 二聚体优化增强了探针在 PC-3 PIP 荷瘤小鼠模型中的肿瘤靶向能力。 与PSMA单体相比，聚乙二醇化PSMA二聚体降低了血液中的消除半衰期，增加了肿瘤中的摄 …
Dose escalation and expansion from the phase I study of DS-1062, …
2020年5月25日 · DS-1062 is a TROP2-targeting ADC with a novel topoisomerase 1 inhibitor (exatecan derivative, DXd) and promising preclinical antitumor activity. Updated results …
Phase 2, Single-arm, Open-label Study of DS-1062a in Advanced …
document results for this mutation or unless osimertinib is not locally approved. the most recent treatment regimen for advanced or metastatic NSCLC. - Participant must meet the following …